Moderna's COVID-19 vaccine sales remain strong, quarterly revenue exceeds expectations
Special Topic: Focus on US Stock Q4 2025 Earnings Reports
Moderna announced on Friday that, thanks to better-than-expected sales of its COVID-19 vaccine in the United States, the company's fourth-quarter revenue exceeded Wall Street expectations.
This Cambridge, Massachusetts-based company, which earned huge profits during the pandemic, has been under financial pressure due to a sharp decline in demand for its COVID-19 vaccine. The company is developing new products to fill the revenue gap and demonstrate the long-term viability of its mRNA technology.
The company reiterated its expectation of achieving 10% revenue growth in 2026.
According to data compiled by LSEG, the vaccine maker's quarterly revenue was $678 million, while analysts on average had expected $626.1 million.
Editor: Guo Mingyu
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Sui holds $1.15 as open interest nears $1 billion after September rally
Tesla’s car business keeps shrinking as Wall Street expects another year-over-year sales drop
The apparent boom in US stocks masks underlying weakness! The S&P 500 is less than 2% from its all-time high, yet small-cap stocks, banks, and utilities sectors suffer heavy losses.
As the yield on the U.S. 10-year Treasury once surged to 5.34%, reaching its highest level since 2002, Wall Street is intensely debating when the bond market sell-off will truly impact the seemingly resilient U.S. stock market.
Crypto prices
More
